Annual results and Q4 2023
Wednesday, January 31, 2024
Media release:
English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB) | Français (PDF 0.3 MB)
Condensed financial report (PDF 0.6 MB)
Download the podcast (MP3 34 MB)
Download the presentation (PDF 5.5 MB)
Novartis Q4 2023 Impact and Sustainability Update (PDF 0.6 MB)
Download 2023 epidemiology data (PDF 1.1 MB)
Key figures1 | Continuing operations2 | ||
---|---|---|---|
Q4 2023 (USD m) | Q4 2022 (USD m) | % change (USD/cc) | |
Net sales | 11,423 | 10,576 | 8 (cc: 10) |
Operating income | 2,582 | 1,755 | 47 (cc: 68) |
Net income | 2,638 | 1,315 | 101 (cc: 130) |
EPS (USD) | 1.29 | 0.62 | 108 (cc: 140) |
Free cash flow | 2,141 | 3,462 | -38 |
Core | |||
Operating income | 3,821 | 3,645 | 5 (cc: 13) |
Net income | 3,126 | 2,963 | 6 (cc: 11) |
EPS (USD) | 1.53 | 1.39 | 10 (cc: 16) |
- Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 49 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.
- As defined on page 37 of the Condensed Financial Report, Continuing operations include the retained business activities of Novartis, comprising the innovative medicines business and the continuing Corporate activities and Discontinued operations include operational results from the Sandoz business.